Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07332546Not ApplicableNot Yet Recruiting

EOIB for Pain After Laparoscopic Cholecystectomy

Role: lead

NCT07187765Not ApplicableCompleted

Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy

Role: lead

NCT07204106Not ApplicableCompleted

Efficacy Study of Dexmedetomidine Nasal Spray Combined With Propofol for Deep Sedation in ERCP

Role: lead

NCT07154979Not ApplicableCompleted

Oliceridine Dose for Tracheal Intubation Hemodynamic Elevation: Up-and-Down Trial

Role: lead

NCT06135545Not ApplicableWithdrawn

Bupivacaine Liposome Serrate Anterior Plane Block vs Traditional Thoracic Paravertebral Block

Role: lead

NCT05631028Not ApplicableCompleted

95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment

Role: lead

All 6 trials loaded